Screener
BioMarin Pharmaceuticals BMRN Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from BioMarin Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's debt-to-equity?
- BioMarin Pharmaceuticals (BMRN) reported debt-to-equity of 0.7× in Q2 2026.
- How has BioMarin Pharmaceuticals's debt-to-equity changed year-over-year?
- BioMarin Pharmaceuticals's debt-to-equity increased by 564.9% year-over-year, from 0.1× to 0.7×.
- What is the long-term trend for BioMarin Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's debt-to-equity has grown at a 50.4% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about BioMarin Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude